The relationship between high-density lipoprotein, bacterial lipopolysaccharide, and tumour necrosis factor-α in patients with acute decompensated heart failure

Archives of Medical Science

Volumn 4, Issue 4, 2008, Pages 380-385

  Zimmermann, Arabel V ^a   Doehner, Wolfram ^a   Pérez, Amalia Vaz ^a   Schmidt, Hendrik ^b   Volk, Hans Dieter ^a   Anker, Stefan D ^a   Rauchhaus, Mathias ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Chronic heart failure; Endotoxin; Immune activation; Lipoproteins

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; BACTERIUM LIPOPOLYSACCHARIDE; C REACTIVE PROTEIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTOXIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NITRATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; WARFARIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENDOTOXEMIA; FUNCTIONAL STATUS; HEART FAILURE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION; PERIPHERAL EDEMA; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 60249086418     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Flegel WA, Wölpl A, Männel DN, Northoff H. Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins. Infect Immun 1989; 57: 2237-45.
2. Northoff H, Flegel WA, Yurttas R, Weinstock C. The role of lipoproteins in the inactivation of endotoxin by serum. Infusionsther Transfusionsmed 1992; 19: 202-3.
3. Quezado ZM, Natanson C, Banks SM, et al. Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock. J Pharmacol Exp Ther 1995; 272: 604-11.
4. Harris HW, Grunfeld C, Feingold KR, Rapp JH. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest 1990; 86: 696-702.
5. Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994; 180: 1025-35.
6. Yang RB, Mark MR, Gray A, et al. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 1998; 395: 284-8.
7. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000; 356: 930-3.
8. Sandek A, Utchill S, Rauchhaus M. The lipoprotein-endotoxin-hypothesis: an update. Arch Med Sci 2007; 3, 4A: S81-90.
9. Rauchhaus M, Koloczek V, Volk HD, Kemp M, Coats AJ, Anker SD. Inflammatory cytokines and the possible immunological role of lipoproteins in chronic heart failure. Int J Cardiol 2000; 76: 125-33.
10. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102: 3060-7.
11. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999; 353: 1838-42.
12. Rauchhaus M, Clark A, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003; 42: 1933-40.
13. Anker SD, Egerer KR, Volk HD, Kox WJ, Poole-Wilson PA, Coats AJ. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997; 79: 1426-30.
14. Su GL, Dorko K, Strom SC, Nüssler AK, Wang SC. CD14 expression and production by human hepatocytes. J Hepatol 1999; 31: 435-42.
15. Peschel T, Schönauer M, Thiele H, Anker SD, Schuler G, Niebauer J. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail 2003; 5: 609-14.
16. Sharma R, Bolger AP, Rauchhaus M, et al. Cellular endotoxin desensitisation in patients with severe chronic heart failure. Eur J Heart Fail 2005; 7: 865-8.
17. Sharma R, von Haehling S, Rauchhaus M, et al. Whole blood endotoxin responsiveness in patients with chronic heart failure: the importance of lipoproteins. Eur J Heart Fail 2005; 7: 479-84.
18. Evans GF, Zuckerman SH. Glucocorticoid-dependent and independent mechanisms involved in lipopolysaccharide tolerance. Eur J Immunol 1991; 21: 1973-9.
19. Vonhof S, Brost B, Stille-Siegener M, Grumbach IM, Kreuzer H, Figulla HR. Monocyte activation in congestive heart failure due to coronary artery disease and idiopathic dilated cardiomyopathy. Int J Cardiol 1998; 63: 237-44.
20. Anker SD, Clark AL, Kemp M, et al. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol 1997; 30: 997-1001.
21. Schumann RR, Leong SR, Flaggs GW, et al. Structure and function of lipopolysaccharide binding protein. Science 1990; 249: 1429-31.
22. Schumann RR, Rietschel ET, Loppnow H. The role of CD14 and lipopolysaccharide-binding protein (LBP) in the activation of different cell types by endotoxin. Med Microbiol Immunol (Berl) 1994; 183: 279-97.
23. Flegel WA, Baumstark MW, Weinstock C, Berg A, Northoff H. Prevention of endotoxin-induced monokine release by human low-and high-density lipoproteins and by apolipoprotein A-I. Infect Immun 1993; 61: 5140-6.
24. Pajkrt D, Doran JE, Koster F, et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 184: 1601-8.
25. Brunkhorst FM, Clark AL, Forycki ZF, Anker SD. Pyrexia, procalcitonin, immune activation and survial in cardiogenic shock: the potential importance of bacterial translocation. Int J Cardiol 1999; 72: 3-10.
26. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119: 771-8.